Halozyme Therapeutics, Inc.
HALO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $354,264 | $325,719 | $264,861 | $298,008 |
| % Growth | 8.8% | 23% | -11.1% | – |
| Cost of Goods Sold | $55,242 | $46,359 | $48,403 | $42,055 |
| Gross Profit | $299,022 | $279,360 | $216,458 | $255,953 |
| % Margin | 84.4% | 85.8% | 81.7% | 85.9% |
| R&D Expenses | $17,251 | $17,543 | $14,799 | $20,441 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $46,088 | $41,614 | $42,362 | $42,249 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $17,762 | $17,762 | $17,762 | $17,762 |
| Operating Expenses | $81,101 | $76,919 | $74,923 | $80,452 |
| Operating Income | $217,921 | $202,441 | $141,535 | $175,501 |
| % Margin | 61.5% | 62.2% | 53.4% | 58.9% |
| Other Income/Exp. Net | $1,037 | $2,497 | $2,293 | $2,713 |
| Pre-Tax Income | $218,958 | $204,938 | $143,828 | $178,214 |
| Tax Expense | $43,733 | $39,778 | $25,733 | $41,202 |
| Net Income | $175,225 | $165,160 | $118,095 | $137,012 |
| % Margin | 49.5% | 50.7% | 44.6% | 46% |
| EPS | 1.49 | 1.36 | 0.96 | 1.08 |
| % Growth | 9.6% | 41.7% | -11.1% | – |
| EPS Diluted | 1.43 | 1.33 | 0.93 | 1.06 |
| Weighted Avg Shares Out | 117,219 | 121,343 | 123,215 | 126,406 |
| Weighted Avg Shares Out Dil | 122,331 | 124,158 | 126,644 | 129,424 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $4,296 | $4,394 | $4,525 | $4,540 |
| Depreciation & Amortization | $61,371 | $20,502 | $20,449 | $20,415 |
| EBITDA | $284,625 | $229,834 | $168,802 | $203,169 |
| % Margin | 80.3% | 70.6% | 63.7% | 68.2% |